After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN
The company had focused its resources on Filspari’s launch in IgAN after the US FDA snubbed the therapy in another rare kidney disorder.
Therapy Area
Investment opportunities in atopic dermatitis may drive innovation
GSK’s asthma blockbuster Nucala secures win in COPD Phase III trial
FDA grants ODD to Abdera’s neuroendocrine carcinoma treatment
NImmune and BioTherapeutics partner on precision medicine development
FDA approves Amneal and Shilpa’s oncology product BORUZU
ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy
Moderna mpox mRNA vaccine shows early promise in monkey study
